US drugmaker Pfizer and its German colleague BioNTech disclosed on Wednesday that their COVID-19 vaccine has revealed “100% efficacy” among children aged between 12-15 precisely.
“We disclosed the occurrence to the authorization of our vaccine to use in younger populations and are persuaded by the clinical trial data from adolescents between the ages of 12 and 15,” Albert Bourla, chairman and chief executive officer of Pfizer, disclosed in a statement.
Report from a US study with 2,260 volunteers reveals that there were no COVID-19 cases among adolescents who were vaccinated, as opposed to 18 infections among those given placebo shots.
Bourla disclosed that the firms are planning to send the results to the US Food and Drug Administration and other regulators around the world in the coming weeks, “with the hope of starting to vaccinate this age group before the start of the next school year.”
Ugur Sahin, CEO and cofounder of BioNTech, said the initial results show that adolescents are “particularly well protected by vaccination.”
“It is very important to allow them to get back to everyday school life and to meet friends and family while protecting them and their loved ones,” he said.
